This indicates that complement was activated up to the level of the terminal pathway and is consistent with previous reports of C4NeF-positive C3G/IC-MPGN patients (16, 17, 34). This evidence concerns the gene RAPGEF1 and primary membranoproliferative glomerulonephritis.